Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
6/1/2026, 12:00:00 AM
Biogen and partner UCB announced that their Phase 3 PHOENYCS GO clinical trial for dapirolizumab pegol met its primary endpoint; a 5-10% price impact is estimated as Phase 3 success in a major indication is a significant catalyst, scheduled.
Korean Translation
바이오젠과 파트너사 UCB, 2026년 6월 1일 전신성 홍반성 루푸스 치료제 3상 성공 발표로 5-10%의 주가 상승이 예상됨.
Related Recent Events
Microchip Technology Inc (MCHP) · Earnings Release
Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.
8/5/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
8/4/2026, 12:00:00 AM
Super Micro Computer Inc (SMCI) · Earnings Release
The Q4 2026 earnings release is scheduled for August 4, 2026. Low importance is estimated as no market reaction has occurred yet for this future date, expected.
8/4/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
Comcast's Q2 2026 earnings release on July 30, 2026 scheduled. Medium importance is estimated as earnings reports often impact stock prices.
7/30/2026, 12:00:00 AM
KLA Corp (KLAC) · Earnings Release
Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.
7/30/2026, 12:00:00 AM